Julie Hoffman
@juliehoffaz
Health Care Policy & Biotech • Strategic Engagement Pro • Advocate & Politico ❤🌵🏈🏀⚾️
ID: 1139550026609254400
14-06-2019 15:07:52
1,1K Tweet
404 Followers
934 Following
TJ Parker⚡️ Concerned PharmD 🇺🇸 For brands , hopefully , there would be no rebates. And if we have to use rebates. The cost we use is the cost after rebates. We have done the math. Employers have no clue what they pay, net, on a claim for a brand. It's mostly done by therapeutic class. If the wac on
Mark Cuban (Mark Cuban) testifies on Pharmacy Benefit Managers (PBMs) before the Senate Full video here: c-span.org/event/senate-c…
Congressional diabetes caucus leaders object to proposed CMS pymt changes for diabetes tech. Journos: Follow the data. Rental of devices isn't about access to new tech. It's about the ownership & marketing of pt data generated by devices. medtechdive.com/news/legislato… via MedTech Dive
Even our colleagues across the country can see #HB2211 striker is a bad bill. #AZLeg Arizona House Republicans Arizona House Democrats AzHHA HSAAZ Arizona Medical Association (ArMA) Arizona Nurses Assoc
Brian Blase is exactly right. Medicare prices are set by politics, not markets, which means hospitals win, insurers win, and physicians lose. And that distortion is driving the healthcare cost crisis, not solving it. Since 2000, the physician conversion factor has gone from
Marion E Mass, M.D. #patientsfirst #scrubsnotsuits Patients have legal & regulatory weight behind requesting their complete health records. But they currently lack the means to receive, organize, or meaningfully share them. They’re on the wrong end of the digital power imbalance. Patients should be able to function as sovereign
Registration is now open for the National Health Council's 2026 Science of Patient Engagement Summit: Turning Evidence into Impact! Join us May 11-12 as we explore how meaningful patient engagement leads to better health care. Register today: bit.ly/4baxmac
Actually, Mark Cuban Cost Plus Drug Company would sell every brand and specialty drug we could. But there are brands and specialty manufacturers that won’t sell to us because your buddies at the PBMs tell them they will diminish them on their formularies. That could cost them billions in some